Hemolytic Uremic Syndrome

Hemolytic Uremic Syndrome

Hemolytic Uremic Syndrome

On this page

Hemolytic Uremic Syndrome: Overview - Tiny Clots, Big Trouble

  • Definition: A critical illness defined by the triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia (platelet count < 150,000/μL), and acute kidney injury (AKI).

  • 📌 Classic Triad: HUS = RAT (Renal failure, Anemia, Thrombocytopenia).

  • Key Types & Etiology:

    FeatureTypical (D+) HUSAtypical (aHUS / D-) HUS
    Prevalence~90% of cases; common in children < 5 years.~10% of cases; can occur at any age.
    Main CauseShiga toxin-producing E. coli (STEC), esp. O157:H7; Shigella dysenteriae.Primarily genetic mutations leading to chronic, uncontrolled complement activation. Other triggers: infections (non-enteric), drugs.
    ProdromeUsually follows acute gastroenteritis with bloody diarrhea (D+).Often no preceding diarrhea (D-); may have insidious onset or be triggered by infections.

⭐ HUS is the most common cause of acute kidney injury (AKI) in young children.

Hemolytic Uremic Syndrome: Pathophysiology - Endothelial Attack Mode

HUS pathogenesis is driven by Shiga toxin (Stx) from bacteria like EHEC. Stx targets vascular endothelial cells, primarily in renal glomeruli and the brain, initiating a damaging cascade.

Shiga toxin mechanism in HUS

  • Toxin Action: Stx absorption from the gut allows it to bind endothelial Gb3 receptors.
  • Cellular Impact: This triggers endothelial damage, apoptosis, and inflammation.
  • Vascular Occlusion: Leads to microthrombi in small vessels (glomeruli).
  • Systemic Effects: Results in consumption of platelets (thrombocytopenia), mechanical RBC damage (schistocytes), and ultimately renal ischemia and AKI.

⭐ Shiga toxin (Stx) binds with high affinity to the glycosphingolipid globotriaosylceramide (Gb3) receptor, predominantly expressed on renal glomerular endothelial cells.

Hemolytic Uremic Syndrome: Clinical & Lab Dx - Spotting the Syndrome

Clinical Presentation:

  • Prodrome:
    • D+ HUS (Typical): Diarrhea (often bloody) post-gastroenteritis (E. coli O157:H7).
    • D- HUS (Atypical/Pneumococcal): Recent URI (S. pneumoniae).
  • Key Symptoms: Pallor, weakness, oliguria/anuria, edema, hypertension.
  • Severe Signs: Petechiae/purpura, irritability, seizures (CNS involvement).

Schistocytes in MAHA peripheral blood smear

Key Laboratory Findings:

Test CategoryFindingSignificance
CBCAnemia (Hb <8-10 g/dL), Thrombocytopenia (<150,000/μL)MAHA, Platelet consumption
Peripheral SmearSchistocytes, helmet cellsRBC fragmentation (hallmark of MAHA)
Hemolysis↑LDH, ↓Haptoglobin, ↑Indirect BilirubinIntravascular hemolysis
Renal Function↑BUN, ↑Creatinine; Hematuria, ProteinuriaAcute Kidney Injury (AKI)
Specific TestsStool (Shiga toxin), ADAMTS13, ComplementIdentify cause (D+ HUS, TTP diff., aHUS)

Hemolytic Uremic Syndrome: Management & Complications - Damage Control & Outlook

⭐ Antibiotic treatment of EHEC infections is generally avoided as it may increase Shiga toxin release and worsen HUS risk; supportive care is the cornerstone for typical (D+) HUS.

Management: Mainstay is supportive care for D+ HUS.

  • Fluid/electrolyte balance (⚠️ caution fluid overload).
  • RBC transfusion if Hb <6-7 g/dL.
  • Platelet transfusion: ONLY for active, severe bleeding (NOT prophylactic).
  • Nutritional support.
  • Hypertension control.
  • Dialysis for severe AKI.
  • aHUS: Eculizumab.
  • AVOID: Antibiotics/antimotility agents in D+ HUS.

Complications:

  • CNS: Seizures, stroke.
  • GI: Colitis, perforation.
  • Pancreatitis.
  • Renal: CKD, hypertension, proteinuria.

Prognosis: Better in D+ HUS with prompt management.

HUS Clinical Pearls

High-Yield Points - ⚡ Biggest Takeaways

  • HUS Triad: Microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury (AKI).
  • Typical HUS (D+ HUS): Caused by Shiga toxin-producing E. coli (STEC), often O157:H7, after bloody diarrhea.
  • Pathophysiology: Toxin-mediated endothelial damage causes microthrombi in renal microvasculature.
  • Key lab finding: Schistocytes on peripheral smear, indicating MAHA.
  • Management: Primarily supportive. Avoid antibiotics and antimotility agents in D+ HUS.
  • Atypical HUS (aHUS): Due to complement dysregulation; may need eculizumab.

Practice Questions: Hemolytic Uremic Syndrome

Test your understanding with these related questions

A child presents with abdominal pain, arthralgia, hematuria, and hypertension. What is the diagnosis?

1 of 5

Flashcards: Hemolytic Uremic Syndrome

1/10

_____ is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure

TAP TO REVEAL ANSWER

_____ is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure

Hemolytic uremic syndrome (HUS)

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial